Targeting human {gamma}delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer. [electronic resource]
Producer: 20070911Description: 7450-7 p. digitalISSN:- 0008-5472
- Aged
- Aged, 80 and over
- Antineoplastic Agents -- therapeutic use
- Bone Density Conservation Agents -- therapeutic use
- Diphosphonates -- therapeutic use
- Dose-Response Relationship, Drug
- Drug Therapy, Combination
- Feasibility Studies
- Humans
- Imidazoles -- therapeutic use
- Immunotherapy -- methods
- Interleukin-2 -- therapeutic use
- Lymphocyte Activation -- drug effects
- Male
- Middle Aged
- Neoplasms, Hormone-Dependent -- drug therapy
- Prostatic Neoplasms -- drug therapy
- Receptors, Antigen, T-Cell, gamma-delta
- Remission Induction
- Salvage Therapy
- T-Lymphocytes -- cytology
- Treatment Outcome
- Zoledronic Acid
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.